Top

Archives of Gynecology and Obstetrics

Published in:

01-10-2017 | Gynecologic Oncology

Feasibility and response to nedaplatin monotherapy in older patients with ovarian cancer

Authors: Hiroyuki Yoshida, Daisuke Shintani, Aiko Ogasawara, Keiichi Fujiwara

Published in: Archives of Gynecology and Obstetrics | Issue 4/2017

Abstract

Purpose

Nedaplatin (NDP), a second-generation platinum analog, has been developed to reduce the toxicity of cisplatin. Although the use of NDP for older patients seems suitable because of the reduced risk of toxicity, few studies have investigated its application to older patients with ovarian cancer (OC). The objective of this study was to compare the tolerability and effectiveness of NDP between patients older and younger than 70 years of age with OC.

Methods

We enrolled 56 patients with OC who were treated with NDP monotherapy and divided them into those who were 70 years and older (n = 18) and younger than 70 years (n = 38). NDP was administered intravenously until disease progression or unacceptable toxicities occurred.

Results

The incidences of grade 3/4 hematological toxicities were significantly higher in the older patients than in the younger patients, including anemia (p = 0.0021), leucopenia (p = 0.029), neutropenia (p = 0.0048), and thrombocytopenia (p = 0.0024). The incidence of elevated creatinine was also significantly higher in the older patients (p = 0.0063). Older patients had significantly more frequent dose reductions (p = 0.017) and treatment interruptions from toxicity (p = 0.04). The tumor response rate for NDP did not differ significantly between younger (29%) and older (28%) patients (p = 0.47). The two age groups also did not significantly differ in progression-free survival (p = 0.27) and overall survival (p = 0.46).

Conclusions

Although NDP is a useful therapeutic option for OC, careful consideration of the adverse effect should be given for patients 70 years and older.

Monson K, Litvak DA, Bold RJ (2003) Surgery in the aged population: surgical oncology. Arch Surg 138:1061–1067CrossRefPubMed

Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9–29CrossRefPubMed

McGuire WP, Hoskins WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1–6CrossRefPubMed

Markman M, Kennedy A, Webster K et al (1999) Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17:1141CrossRefPubMed

Niioka T, Uno T, Yasui-Furukori N et al (2007) Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with nonsmall-cell lung carcinoma. Cancer Chemother Pharmacol 59:575–580CrossRefPubMed

Furuse K, Fukuoka M, Kurita Y et al (1992) A phase II clinical study of cis-diammineglycolatoplatinum, 254-S, for primary lung cancer. Jpn J Cancer Chemother 19:879–884

Taguchi T, Wakui A, Nabeya K et al (1992) A phase II clinical study of cis-diammineglycolatoplatinum, 254-S, for gastrointestinal cancers. Jpn J Cancer Chemother 19:483–488

Noda K, Ikeda M, Yakushiji M et al (1992) A phase II clinical study of cis-diammineglycolatoplatinum, 254-S, for cervical cancer of the uterus. Jpn J Cancer Chemother 19:885–892

Koshiyama M, Kinezaki M, Uchida T et al (2005) Chemosensitivity testing of a novel platinum analog, nedaplatin (254-S), in human gynecological carcinomas: a comparison with cisplatin. Anticancer Res 25:4499–4502PubMed

10.

Kato T, Nishimura H, Yakushiji M et al (1992) Phase II study of 254-S (cis-diammineglycolatoplatinum) for gynecological cancer. Gan To Kagaku Ryoho 19:695–701PubMed

11.

Itoh K, Yamashita T, Wakita H et al (1998) Successful treatment with nedaplatin in patients with ovarian cancer that recurred after platinum-containing chemotherapy: report of two cases. Jpn J Clin Oncol 28:343–346CrossRefPubMed

12.

Goto T, Takano M, Ohishi R et al (2010) Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers. J Obstet Gynaecol Res 36:764–768CrossRefPubMed

13.

Alberts DS, Fanta PT, Running KL et al (1997) In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers. Cancer Chemother Pharmacol 39:493–497CrossRefPubMed

14.

Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105:103–104CrossRefPubMed

15.

National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40. Accessed 26 July 2016

16.

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMed

17.

Goldberg RM, Tabah-Fisch I, Bleiberg H et al (2006) Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24:4085–4091CrossRefPubMed

18.

Kabbinavar FF, Schulz J, McCleod M et al (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23:3697–3705CrossRefPubMed

19.

Pinder MC, Duan Z, Goodwin JS et al (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808–3815CrossRefPubMed

20.

Muss HB, Woolf S, Berry D et al (2005) Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073–1081CrossRefPubMed

21.

Fairfield KM, Murray K, Lucas FL et al (2011) Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer. J Clin Oncol 29:3921–3926CrossRefPubMed

22.

Sundararajan V, Hershman D, Grann VR et al (2002) Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol 20:173–178CrossRefPubMed

23.

Eisenhauer EL, Tew WP, Levine DA et al (2007) Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol Oncol 106:381–387CrossRefPubMed

24.

Yamamoto N, Tamura T, Kurata T et al (2009) A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 65:79–88CrossRefPubMed

25.

Callahan MB, Lachance JA, Stone RL et al (2007) Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. Am J Obstet Gynecol 197:199.e1–199.e5

26.

Dizon DS, Sabbatini PJ, Aghajanian C et al (2002) Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 84:378–382CrossRefPubMed

27.

Zweizig S, Roman LD, Muderspach LI (1994) Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol 53:121–122CrossRefPubMed

28.

Michikami H, Minaguchi T, Ochi H et al (2013) Safety and efficacy of substituting nedaplatin after carboplatin hypersensitivity reactions in gynecologic malignancies. J Obstet Gynaecol Res 39:330–335CrossRefPubMed

29.

Joly F, Ray-Coquard I, Fabbro M et al (2011) Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecol Oncol 122:226–232CrossRefPubMed

30.

Yoshida H, Imai Y, Fujiwara K (2016) Combination chemotherapy with docetaxel and carboplatin for elderly patients with endometrial cancer. Mol Clin Oncol 4:783–788CrossRefPubMedPubMedCentral

31.

Fader AN, von Gruenigen V, Gibbons H et al (2008) Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol 109:33–38CrossRefPubMed

Title: Feasibility and response to nedaplatin monotherapy in older patients with ovarian cancer
Authors: Hiroyuki Yoshida
Daisuke Shintani
Aiko Ogasawara
Keiichi Fujiwara
Publication date: 01-10-2017
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 4/2017
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-017-4487-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Feasibility and response to nedaplatin monotherapy in older patients with ovarian cancer

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2017

Pathobiology of myomatosis uteri: the underlying knowledge to support our clinical practice

Expression of H19 imprinted gene in patients with repeated implantation failure during the window of implantation

Patients’ experience of breast reconstruction after mastectomy and its influence on postoperative satisfaction

Principles of first trimester screening in the age of non-invasive prenatal diagnosis: screening for chromosomal abnormalities

Palliative care in ovarian carcinoma patients—a personalized approach of a team work: a review

Topic anaesthesia with a eutectic mixture of lidocaine/prilocaine cream after elective caesarean section: a randomised, placebo-controlled trial